Your gateway to a free society
Article

James O'Keefe OUT From Project Veritas, After Being Placed on Paid Leave By the Board

Back

aboutLiberty Portal

Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Feb 22, 2026 / Dave DeCamp
Fourteen Countries Condemn Huckabee’s Support for Israel Taking Over Most of the Middle East
US Ambassador to Israel Mike Huckabee has sparked a diplomatic firestorm, drawing a rebuke from 14 countries after expressing support for the idea of Israel taking over land stretching from Egypt to Iraq during an interview with Tucker Carlson. Huckabee made the comments when pressed on his Christian Zionist view that the modern state of […]
Read more
Feb 21, 2026 / Tyler Durden
Deporting Censorship: US Targets UK Government Ally Over Free Speech
Deporting Censorship: US Targets UK Government Ally Over Free Speech Authored by Paul D. Thacker via RealClearInvestigations, As ICE sweeps in Minneapolis have drawn wide attention, a little-noticed immigration case playing out in a New York federal court has significant implications for America’s relationship with Britain and the ongoing debate over global censorship.   In late December, the State Department announced its intention to revoke the visas of five foreign individuals who have allegedly censored Americans. The most consequential member of this group is Imran Ahmed, a British Labour Party political operative now...
Read more
Feb 24, 2026 / Tyler Durden
Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs
Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs Novo Nordisk shares in Copenhagen can't catch a bid. The liquidation is accelerating again after a Bloomberg headline on Tuesday morning: the Danish drugmaker will slash U.S. list prices for Wegovy and Ozempic next year. The move suggests that the new CEO is pursuing market share amid intensifying competition in the GLP-1 space. Jamey Millar, Novo's head of U.S. operations, was quoted by Bloomberg as saying the company set a monthly price of $675 for its family of semaglutide drugs,...
Read more

support

If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.